Lexeo Therapeutics, Inc. LXEO
Regular-session close
Pre-market · Nov 20, 8:23 AM ET
- YTD
- -70.29%
- 1 year
- -67.55%
5D +0.12 (+4.15%)
- Market cap
- 244.23M
- EPS (ttm)
- -1.13
- Shares out
- 33.08M
- Forward P/E
- -2.24
- YTD return
- -70.29%
- 1-year return
- -67.55%
- 50-day average
- 7.92
- Volume
- 1.28M
- Avg volume
- 1.96M
- Open
- 2.93
- Previous close
- 2.95
- Day's range
- 2.87 – 3.21
- 52-week range
- 2.55 – 10.99
- Price target
- 22.29 (+655.4%)
Key statistics
- 200-day average
- 11.86
- Enterprise value
- 90.11M
- Price / book
- 1.46
- Free cash flow
- -36.83M
- Total cash
- 174.98M
- Total debt
- 10.85M
- Return on equity
- -74.83%
- Short % of float
- 7.42%
Fundamental scorecard
5 of 25 checks passed on LXEO’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.65 | -0.89 | -0.24 | -36.92% |
| May 9, 2024 | Mar 1, 2024 | -0.76 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.76 | -0.77 | -0.01 | -1.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 13, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 13, 2024 | Leerink Partners | main | Outperform | Outperform |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 30, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 25, 2024 | Chardan Capital | main | Buy | Buy |
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lexeotx.com
News
Lexeo Therapeutics: Encouraging Gene Therapy Data, But I Want To See More
Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
Lexeo Therapeutics Q3 Earnings Call Highlights Cantor Fitzgerald Maintains Overweight on Lexeo Therapeutics, Raises Price Target to $37
Lexeo Therapeutics Announces Interim Data From Its Ongoing HEROIC-PKP2 Phase I/II Clinical Trial Of LX2020 For Treatment Of PKP2 Arrhythmogenic Cardiomyopathy; Across Ten Participants, Including Nine With At Least 12 Months Of Follow-up, Treatment With LX2020 Was Generally Well Tolerated
12 Health Care Stocks Moving In Monday's Pre-Market Session Lexeo Therapeutics Q3 EPS $(0.43) Misses $(0.33) Estimate
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
Your note
Sign in to keep a note on LXEO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADLER ERIC | Officer | Stock Award(Grant) | Feb 1, 2024 | 26,875 |
| CHOLMONDELEY PAULA H. J. | Director | Purchase | Nov 24, 2024 | 30,627 |
| LONGITUDE CAPITAL PARTNERS IV, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 6, 2023 | 0 |
| LUNDBECKFOND INVEST AS | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 6, 2023 | 1,835,960 |
| MCCORMAC PAUL | Chief Technology Officer | Conversion of Exercise of derivative security | Nov 6, 2023 | 17,349 |
| OMEGA FUND VI, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 6, 2023 | 2,157,620 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 11.38% | 3,763,195 | 23.37M | Sep 29, 2024 |
| Citadel Advisors Llc | 8.24% | 2,723,363 | 16.91M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 7.86% | 2,597,736 | 16.13M | Sep 29, 2024 |
| D1 Capital Partners, LP | 7.58% | 2,506,607 | 15.57M | Sep 29, 2024 |
| Omega Fund Management, Llc | 7.12% | 2,355,904 | 14.63M | Sep 29, 2024 |
| Eventide Asset Management LLC | 5.61% | 1,855,986 | 11.53M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 4.61% | 1,525,517 | 9.47M | Sep 29, 2024 |
| Janus Henderson Global Life Sciences Fund | 2.21% | 731,182 | 4.54M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.80% | 595,877 | 3.70M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.22% | 404,869 | 2.51M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.82% | 272,700 | 1.69M | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.59% | 194,828 | 1.21M | Oct 30, 2024 |
